BLX 0871
Alternative Names: BLX-0871; MLX-0800; MLX-0871Latest Information Update: 31 Oct 2024
Price :
$50 *
At a glance
- Originator Biolexis Therapeutics
- Class Antihyperglycaemics; Obesity therapies; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity; Type 2 diabetes mellitus
Most Recent Events
- 29 Oct 2024 Biolexis Therapeutics announces intention to submit IND for Obesity and Type 2 diabetes
- 29 Oct 2024 Pharmacodynamics data from a preclinical study in Obesity and Type 2 diabetes released by Biolexis Therapeutics
- 21 Jun 2024 Biolexis Therapeutics plans a first in human phase I trial for Type 2 diabetes mellitus and obesity (PO) in Q2 2025